Clinical experience with excitatory amino acid antagonist drugs

Stroke

Volumn 26, Issue 3, 1995, Pages 503-513

  Muir, Keith W ^a   Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

cerebral ischemia; clinical trials; drug therapy; excitatory amino acids

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 AMINOCYCLOPROPANECARBOXYLIC ACID; 1 METHYL 1,2 DIPHENYLETHYLAMINE; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 3 AMINO 1 HYDROXY 4 METHYL 2 PYRROLIDINONE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; APTIGANEL; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; ELIPRODIL; ENADOLINE; ETICYCLIDINE; FELBAMATE; FLP 12495; LAMOTRIGINE; LUBELUZOLE; MAGNESIUM; MEMANTINE; N ALLYLNORMETAZOCINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; RILUZOLE; SIPATRIGINE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; BRAIN PROTECTION; CARDIOVASCULAR EFFECT; DRUG MECHANISM; HUMAN; HYPOTENSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; STROKE;

EID: 0028897733     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.26.3.503     Document Type: Review

References (118)

1. Lipton SA, Rosenberg PA. Mechanisms of disease: excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
2. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362.
3. Albers GW, Goldberg MP, Choi DW. N-methyl-D-aspartate antagonists: ready for clinical trial in brain ischemia? Ann Neurol. 1989;25:398-403.
4. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci. 1984;4: 1884-1891.
5. Olney JR. Neurotoxicity of excitatory amino acids. In: McGreer EG, Olney JW, McGreer PJ, eds. Kainic Acid as a Tool in Neurobiology. New York, NY: Raven Press; 1978:95-171.
6. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett. 1985;58:293-297.
7. Hossmann KA. Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised. Brain Pathol. 1994;4:23-36.
8. Greene JG, Porter RHP, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an 'excitotoxic' lesion in rat striatum. J Neurochem. 1993;61:1151-1154.
9. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42:733-738.
10. Beal MF. Does impairment of energy metabolism result in exci totoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992;31:119-130.
11. Baker AJ, Moulton RJ, MacMillan VH, Shedden PM. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurg. 1993;79:369-372.
12. Bullock R, Zauner A, Marmarou A, Woodward JJ, Young HF. Evidence for prolonged release of excitatory amino acids in severe human head trauma: relationship to clinical events. In: Proceedings of the 2nd International Conference on Neuroprotective Agents; July 31, 1994; Lake George, NY. Abstract.
13. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol. 1992;34:106-114.
14. Foster AC, Fagg GE. Taking apart NMDA receptors. Nature. 1987;329:395-396.
15. Kornhuber J, Bormann J, Lipton SA. Neuroprotective effects of memantine. Neurology. 1993;43:1054-1055. Letter.
16. Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992;12:4427-4436.
17. Minematsu K, Fisher M, Li L, Davis MA, Knapp AG, Cotter RE, McBurney RN, Sotak CH. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology. 1993;43:397-403.
18. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol. 1988;24:543-551.
19. Pulsinelli W, Sarokin A, Buchan A. Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. Prog Brain Res. 1993;96:125-135.
20. Greifenstein FE, DeVault M, Yoshitake J, Gajewski JE. A study of 1-aryl cyclohexylamine for anesthesia. Anesth Analg. 1958;37:283-294.
21. Johnstone M, Evans V, Baigel S. Sernyl (CI-395) in clinical anaesthesia. Br J Anaesth. 1959;31:433-439.
22. Fauman MA, Fauman BJ. Chronic phencyclidine (PCP) abuse: a psychiatric perspective. In: Domino EF, ed. PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, Mich: NPP Books; 1981:419-436.
23. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatr. 1959;81:363-369.
24. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
25. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci. 1990;11:81-86.
26. Domino EF. Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists. J Psychopharmacol. 1992;6:418-424.
27. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260:1209-1213.
28. Albin MS, Bunegin L, Garcia C. Ketamine and postanesthetic emergence reactions. In: Domino EF, ed. Status of Ketamine in Anesthesiology. Ann Arbor, Mich: NPP Books; 1990:17-25.
29. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology. 1982;56:119-136.
30. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain. 1994;56:51-57.
31. Bion JF. Infusion analgesia for acute war injuries: a comparison of pentazocine and ketamine. Anaesthesia. 1984;39:560-564.
32. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine. in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
33. Kochs E, Werner C, Hoffman WE, Mollenberg O, Schulte am Esch J. Concurrent increases in brain electrical activity and intracranial blood flow velocity during low-dose ketamine anaesthesia. Can J Anaesth. 1991;38:826-830.
34. Hougaard K, Hansen A, Brodersen P. The effect of ketamine on regional cerebral blood flow in man. Anesthesiology. 1974;41: 562-567.
35. Stefansson T, Wickstrom I, Haljamae H. Hemodynamic and metabolic effects of ketamine anesthesia in the geriatric patient. Acta Anaesthesiol Scand. 1982;26:371-377.
36. Hornchen U, Tauberger G. Untersuchungen zum Mechanismus der Wirkungen von Ketamine (Ketanest(R)) auf den Kreislauf und die Atmung. Anaesthesist. 1980;29:547-551.
37. Doenicke A, Angster R, Mayer M, Adams HA, Grillenberger G, Nebauer AE. Die Wirkung von S-(+)-Ketamin auf Katecholamine und Cortisol im Serum: Vergleich zu Ketaminrazemat. Anaesthesist. 1992;41:597-603.
38. Pipkin FB, Waldron BA. Ketamine hypertension and the reninangiotensin system. Clin Exp Hyperten [A]. 1983;5:875-883.
39. Lundy PM, Lockwood PA, Thompson G, Frew R. Differential effects of ketamine isomers on neuronal and extraneuronal catecholamine uptake mechanisms. Anesthesiology. 1986;64:359-363.
40. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36:186-197.
41. Rock MJ, de la Rocha SR, L'Hommedieu CS, Truemper E. Use of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapy. Crit Care Med. 1986;14: 514-516.
42. Pedersen T, Hicquet J. Influence du diazepam sur les effets cardiovasculaires et psychotomimetiques de la ketamine administrée en infusion continue: étude en double aveugle. Anesthesie, Analgesie, Reanimation. 1981;38:321-325.
43. Erdmann W, Salt PJ, Agoston S, Langrehr D. Antagonism of the cardiovascular effects of ketamine by diazepam in volunteers. Acta Anaesthesiol Belg. 1979;30:239-245.
44. Munro HM, Sleigh JW, Paxton LD. The cardiovascular response to ketamine: the effects of clonidine and lignocaine. Acta Anaesthesiol Scand. 1993;37:75-78.
45. Gold MI, Brown M, Coverman S, Herrington C. Heart rate and blood pressure effects of esmolol after ketamine induction and intubation. Anesthesiology. 1986;64:718-723.
46. Ozyurt E, Graham DI, Woodruff GN, McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab. 1988;8:138-143.
47. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. Focal cerebral ischaemia in the cat: treatment with the glutamate antagonist MK-801 after induction of ischaemia. J Cereb Blood Flow Metab. 1988;8:757-762.
48. Troupin AS, Mendius JR, Cheng F, Risinger MW. MK-801. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drugs. London, England: John Libbey; 1986:191-201.
49. Reimherr FW, Wood DR, Wender PH. The use of MK 801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol Bull. 1986;22:237-242.
50. Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol. 1994;38:33-38.
51. Grosset DG, Muir KW, Lees KR. Systemic and cerebral hemodynamic responses to the non-competitive NMDA antagonist CNS 1102. J Cardiovasc Pharmacol. 1994. In press.
52. Fisher M. Cerestat (CNS 1102), a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study. Cerebrovasc Dis. 1994;4:245. Abstract.
53. Wagstaff A, Teasdale GM, Clifton G, Stewart L. The cerebral haemodynamic and metabolic effects of the non-competitive NMDA antagonist CNS 1102 in humans with severe head injury. In: Proceedings of the 2nd International Conference on Neuroprotective Agents; July 31, 1994; Lake George, NY. Abstract.
54. Carpenter CL, Marks SS, Watson DL, Greenberg DA. Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res. 1988;439:372-375.
55. Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci. 1989;10:501-507.
56. Albers GW, Saenz R, Moses J Jr, Choi DW. Pilot study of oral dextromethorphan in patients at risk for brain ischemia. Neurology. 1990;40(suppl 1):193. Abstract.
57. Walker F, Hunt V. An open-label escalating dose study of dextromethorphan in Huntington's disease. Ann Neurol. 1989;26:143. Abstract.
58. Steinberg GK, Bell T. Clinical dose escalation safety study of the NMDA antagonist dextromethorphan in neurosurgical patients. Stroke. 1992;23:141. Abstract.
59. Church J. Neuromodulatory effects of dextromethorphan: role of NMDA receptors in responses. Trends Pharmacol Sci. 1990;11: 146-147.
60. Schmitt B, Netzer R, Fanconi S, Baumann P, Boltshauser E. Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients. J Neurol Neurosurg Psychiatry. 1994;57:333-339.
61. Albers GW, Atkinson R, Kelley R, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl D-aspartate antagonist dextrorphan in patients with an acute stroke. Neurology. 1994;44(suppl 2):A270-A271.
62. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartatc (NMDA) receptor channels. Eur J Pharmacol. 1989;166: 591-592.
63. Seif el Nasr M, Peruche B, Rossberg C, Mennel HD, Krieglstein J. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol. 1990;185:19-24.
64. Memantine hydrochloride. Drugs of Today. 1983;19:303-305.
65. Riederer P, Lange KW, Kornhuber J, Danielczyk W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet. 1991;338:1022-1023. Letter.
66. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1992;4:277-282.
67. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. Arzneimittelforschung. 1992;42:904-913.
68. Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:87-93.
69. Palmer GC, Clark B, Hutchison JB. Antiepileptic and neuroprotective potential of remacemide hydrochloride. Drugs of the Future. 1993;18:1021-1042.
70. Heyn H, McCarthy DJ, Curry SH, Eisman MS, Anders MW. Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant. Drug Metab Dispos. 1994;22:443-446.
71. Muir KW, Lees KR. Initial experience with remacemide hydrochloride in patients with acute ischaemic stroke. In: Proceedings of the 2nd International Conference on Neuroprotective Agents; July 31, 1994; Lake George, NY. Abstract.
72. Kurumaji A, McCulloch J. Effects of MK-801 upon local cerebral glucose utilization in conscious rats and in rats anesthetized with halothane. J Cereb Blood Flow Metab. 1989;9:786-794.
73. Auer RN, Coulter KC. The nature and time course of neuronal vacuolation induced by the N-mcthyl-D-aspartate antagonist MK-801. Acta Neuropathol (Berl). 1994;87:1-7.
74. Sharp FR, Jasper P, Hall J, Noble L, Sagar SM. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol. 1991;30:801-809.
75. Kurumaji A, Ikeda M, Dewar D, McCormack AG, McCulloch J. Effects of chronic administration of MK-801 upon local cerebral glucose utilisation and ligand binding to the NMDA receptor complex. Brain Res. 1991;563:57-65.
76. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, Farber N, Wozniak DF, Olney JW. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol. 1993;123:204-215.
77. Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res. 1993;18:1263-1269.
78. Duval D, Roome N, Gauffeny C, Nowicki JP, Scatton B. SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons. Neurosci Lett. 1992;137:193-197.
79. Hargreaves RJ, Rigby M, Smith D, Hill RG. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br J Pharmacol. 1993;110:36-42.
80. Schorn TOF, Whitwam JG. Are there long-term effects of ketamine on the central nervous system? Br J Anaesth. 1980;52: 967-968.
81. Jansen KLR. Ketamine - can chronic use impair memory? Int J Addict. 1990;25:133-139.
82. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515-1518.
83. Wester PO, Asplund K, Eriksson S, Hagg E, Lithner F, Strand T. Infusion of magnesium in patients with acute brain infarction. Acta Neurol Scand. 1985;143. Abstract.
84. Muir KW, Lees KR. Intravenous magnesium sulphate in acute stroke: a randomised, double-blind, placebo-controlled pilot study. Cerebrovasc Dis. 1994;4:255. Abstract.
85. Kristensen JD, Svensson B, Gordh T Jr. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain. 1992;51:249-253.
86. Oye I, Mathisen LC, Kristensen JD, Gordh T. The effect of CPP in neurogenic pain: inhibition of spinal or cortical NMDA receptors? Pain. 1993;53:358-360.
87. Taylor CP. Mechanism of action of new anti-epileptic drugs. In: Chadwick D, ed. New Trends in Epilepsy Management: The Role of Gabapentin. London, England: Royal Society of Medicine; 1994:13-40.
88. Steinberg GK, Perez-Pinzon MA, Maier CM, Sun GH, Yoon E, Kunis DM, Bell TE, Powell M, Kotake A, Giffard R. CGS 19755: correlation of in vitro neuroprotection, protection against experimental ischemia and CSF levels in cerebrovascular surgery patients. In: Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia; July 20, 1994; Marburg, Germany. GLU 4. Abstract.
89. Clark WM, Coull BM. Randomised trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment. Neurology. 1994;44(suppl 2):A270. Abstract.
90. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325:529-531.
91. Kemp JA, Leeson PD. The glycine site of the NMDA receptor - five years on. Trends Pharmacol Sci. 1993;14:20-25.
92. Foster AC, Willis CL, Tridgett R. Protection against N-methyl-D-aspartate receptor-mediated neuronal degeneration in rat brain by 7-chlorokynurenate and 3-amino-l-hydroxypyrrolid-2-one, antagonists at the allostcric site for glycine. Eur J Neurosci. 1990;2:270-277.
93. Chen J, Graham S, Moroni F, Simon R. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. J Pharmacol Exp Ther. 1993;267:937-941.
94. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartatc and gamma-aminobutyric acid(A) receptors. Ann Neurol. 1994;35:229-234.
95. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures [see comments]. Ann Neurol. 1992;32:386-392.
96. Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991;41:1785-1789.
97. Scatton B. Eliprodil. In: Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia; July 20. 1994; Marburg, Germany.
98. Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 1993;16:527-532.
99. Aizenman E, Hartnett KA, Reynolds IJ. Oxygen free radicals regulate NMDA receptor function via a redox modulatory site. Neuron. 1990;5:841-846.
100. Lepagnol J, Lestage P, Cordi A. Cerebral anti-ischemic effects of S 17625, a new selective AMPA antagonist. In: Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia; July 20, 1994; Marburg, Germany. Glu 14. Abstract.
101. Bullock R, Graham DI, Swanson S, McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab. 1994;14:466-471.
102. Graham JL, Smith SE, Pearce PC, Chapman AG, Meldrum BS. Effect of lamotrigine on amino acid concentrations after middle cerebral artery occlusion in the rat: a microdialysis and histological study. In: Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia; July 20, 1994; Marburg, Germany. Neu 1. Abstract.
103. Lekieffre D, Meldrum BS. The pyrimidine-derivative, BW1003C87, protects CA1 and striatal neurons following transient severe forebrain ischaemia in rats: a microdialysis and histological study. Neuroscience. 1993;56:93-99.
104. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke. 1993;24:1063-1067.
105. Torp R, Arvin B, Le Peillet E, Chapman AG, Ottersen OP, Meldrum BS. Effect of ischaemia and reperfusion on the extra- and intra-cellular distribution of glutamate, glutamine, aspartate and GABA in the rat hippocampus, with a note on the effect of the sodium channel blocker BW 1003C87. Exp Brain Res. 1993;96:365-376.
106. Mercer AJ, Lamb RJ, Hobbiger S, Posner J. The tolerability, pharmacokinetics and pharmacodynamics of increasing doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers. In: Proceedings of the 2nd International Conference on Neuroprotective Agents; July 31, 1994; Lake George, NY. Abstract.
107. Muir KW, Lees KR, Hamilton SJC, George CF, Hobbiger S, Lunnon MW. A randomised, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke. In: Proceedings of the 2nd International Conference on Neuroprotective Agents; July 31, 1994; Lake George, NY. Abstract.
108. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comments]. N Engl J Med. 1994;330:585-591.
109. Rowland LP. Riluzole for the treatment of amyotrophic lateral sclerosis-too soon to tell? N Engl J Med. 1994;330:636-637. Editorial.
110. Park CK, McBurney RN, Holt WF, Cotter RE, McCulloch J, Kang JK, Choi CR. The dose-dependency of the antiischemic efficacy and of the side effects of a novel NMDA antagonist, CNS 1102. J Cereb Blood Flow Metab. 1993;13:5641. Abstract.
111. Bubser M, Keseberg U, Notz PK, Schmidt WJ. Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol. 1992;229:75-82.
112. Chen MH, Bullock R, Graham DI, Frey P, Lowe D, McCulloch J. Evaluation of a competitive NMDA antagonist (D-CPPene) in feline focal cerebral ischemia. Ann Neurol. 1991;30:62-70.
113. Wahlgren NG, MacMahon DG, DeKeyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1994;4:204-210.
114. Marchai G, Serrati C, Rioux P, Petit-Taboue MC, Viader F, de la Sayette V, le Doze F, Lochon P, Derlon JM, Orgogozo JM, Baron JC. PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet. 1993;341: 925-927.
115. Baird AE, Donnan GA. Prognostic value of reperfusion during first 48 hours of ischaemic stroke. Lancet. 1993;342:236. Letter.
116. Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab. 1992;12:193-203.
117. Fisher M, Jones S, Sacco RL. Prophylactic neuroprotection for cerebral ischemia. Stroke. 1994;25:1075-1080.
118. Byer DE, Gould AB. Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology. 1981;54: 255-256.